Actemra biosimilars access guide: tocilizumab IV vs SC benefit split, Tyenne/Tofidence/Avtozma payer switching, rheumatology step edits, and preferred-product policies

Actemra (tocilizumab, Genentech/Roche) is an interleukin-6 (IL-6) receptor antagonist approved for rheumatoid arthritis (RA), giant cell arteritis (GCA), polyarticular juvenile idiopathic arthritis (pJIA), systemic juvenile idiopathic arthritis (sJIA), cytokine release syndrome (CRS), systemic sclerosis-associated interstitial lung disease (SSc-ILD), and COVID-19. It is available in both intravenous (IV) and subcutaneous (SC) formulations.

Three biosimilars are now FDA-approved: Tyenne (tocilizumab-aazg, Fresenius Kabi), Tofidence (tocilizumab-bavi, Biogen), and Avtozma (tocilizumab-anoh, Celltrion). But indication coverage, route availability, and interchangeability status vary across the three. Payer preferred-product policies have moved quickly — many major payers now require a biosimilar as first-line tocilizumab.

This guide covers the tocilizumab biosimilar landscape, benefit routing, HCPCS coding, payer switching rules, and access-program routing.

Quick comparison

Indication and route gaps

Several critical differences affect prescribing and payer coverage:

Tofidence is IV only. Because Tofidence has no subcutaneous formulation, it cannot be used for patients on SC Actemra — a significant limitation for RA and GCA patients who self-inject at home. Payers that designate Tofidence as preferred for IV tocilizumab still require a different product for SC.

Tofidence does not carry CRS or SSc-ILD indications. Patients needing tocilizumab for CAR-T–related cytokine release syndrome must use Actemra, Tyenne, or Avtozma. SSc-ILD is similarly excluded. Tofidence received supplemental approval for GCA and COVID-19 in July 2024, expanding beyond its initial RA/pJIA/sJIA indications.

Tyenne does not carry SSc-ILD. The only FDA-approved product for systemic sclerosis–associated interstitial lung disease is Actemra SC. If a payer designates Tyenne as preferred for all RA/GCA/pJIA/sJIA use, SSc-ILD patients still require Actemra.

Avtozma carries the broadest indication set among biosimilars. It includes RA, GCA, pJIA, sJIA, CRS, and COVID-19 — matching Actemra on everything except SSc-ILD. It also has both IV and SC presentations (pre-filled syringe and autoinjector). The SC autoinjector was approved under a supplement (BLA 761498) received May 2025 with a BsUFA goal date of May 2026.

IV vs SC benefit routing

Tocilizumab splits across medical and pharmacy benefit depending on route:

For IV infusions, the practice buys or orders the drug and bills under the medical benefit with the appropriate J-code or Q-code. For SC injections, most commercial plans route through the pharmacy benefit via a specialty pharmacy, although some medical-benefit policies still cover SC tocilizumab.

This split matters for prior authorization: IV and SC may require separate PA submissions on different benefit channels with different criteria.

HCPCS coding

For a typical 80 kg RA patient receiving 8 mg/kg IV tocilizumab (640 mg dose): bill J3262 × 640 units for Actemra IV, Q5135 × 640 units for Tyenne IV, or Q5156 × 640 units for Avtozma IV.

Aetna, UnitedHealthcare, and Cigna all list these codes in their coverage policies. UnitedHealthcare's community plan policy (effective April 2026) requires Tofidence or Tyenne as preferred products, with Actemra and Avtozma requiring step-through documentation.

Payer preferred-product policies

Payer adoption of tocilizumab biosimilar preference has accelerated through 2025 and into 2026:

Blue Cross Blue Shield of Michigan (effective June 2025): Tyenne is the preferred tocilizumab product for both pharmacy and medical benefits. Actemra IV became non-preferred. Active authorizations for Actemra IV were transitioned to Tyenne IV under medical benefits. SC Actemra was removed from coverage for commercial members, with Tyenne SC as the replacement. Members on a plan using the Preferred Drug List are excluded. Filling is restricted to Walgreens Specialty Pharmacy.

Mass General Brigham Health Plan (effective May 2026): Tyenne is the preferred tocilizumab product. Approval of Actemra, Avtozma, or Tofidence requires trial and failure with Tyenne, including in renewal criteria. The policy applies to both IV and SC routes.

Independence Blue Cross (effective July 2025): For commercial members, Actemra IV became non-preferred under the medical benefit. All existing authorizations for Actemra IV were transitioned to Tyenne. Pharmacy benefit coverage continues for both Actemra and Tyenne SC.

UnitedHealthcare (commercial, effective March 2026): Updated tocilizumab policy lists preferred products, with any FDA-approved tocilizumab biosimilar not yet reviewed by UHC considered non-preferred. For the community plan (effective April 2026), Tofidence or Tyenne are preferred; Actemra and Avtozma require documented trial and failure.

Arkansas Blue Cross and Blue Shield (effective January–April 2026): Actemra, Avtozma, Tofidence, and Tyenne are all listed, with biosimilars preferred where there is an FDA-approved indication. Actemra remains available for CRS and SSc-ILD where biosimilar indication coverage is incomplete.

Health Net (Medicaid): Requires member trial of Actemra first, then trial of a preferred adalimumab product, before approving any tocilizumab biosimilar — a more restrictive policy than most commercial payers.

Rheumatology step therapy

Before any tocilizumab product — reference or biosimilar — most payers require:

1. DMARD failure: Trial of at least one conventional synthetic DMARD (methotrexate, sulfasalazine, leflunomide, or hydroxychloroquine) at adequate dose and duration.
2. Biologic or targeted therapy history: Many policies require trial of at least one TNF inhibitor (adalimumab, etanercept, infliximab, certolizumab, golimumab) or a JAK inhibitor before approving tocilizumab.
3. Rheumatologist prescribing: Prescribed by or in consultation with a rheumatologist.
4. No combination biologic use: Patient must not be receiving another biologic or targeted immunomodulator concurrently.

For GCA specifically, some payers (including Mass General Brigham Health Plan, updated September 2025) require trial and failure with corticosteroids before tocilizumab approval.

CRS indication routing

Tocilizumab for CAR-T–induced cytokine release syndrome is a unique indication:

• Actemra IV and Tyenne IV carry CRS on their labels.
• Avtozma IV also carries CRS.
• Tofidence does not carry CRS.

Oncology and cell-therapy teams prescribing tocilizumab for CRS should verify that the ordered product carries the indication. Payer coverage for CRS typically follows the same medical-benefit buy-and-bill pathway as IV infusions in rheumatology, but PA requirements may differ (some payers do not require prior PA for CRS given its urgent nature).

Manufacturer support programs

• Genentech Access Solutions: Benefit verification, PA assistance, copay support, and patient assistance for Actemra. Genentech reports 93% of RA patients have parity coverage for Actemra IV relative to biosimilars.
• Fresenius Kabi (Tyenne): Provides benefit verification and patient support for Tyenne. As the most widely preferred biosimilar, Tyenne's access program is critical for patients transitioning from Actemra.
• Celltrion (Avtozma): Patient support programs available. Avtozma IV launched in the U.S. in August 2025 per patent settlement. SC launch date remains confidential under license agreement with Genentech.
• Biogen (Tofidence): IV-only product. Support programs available through Biogen's biosimilar access team.

Key takeaways for access teams

1. Tyenne is the most preferred biosimilar. It carries the broadest payer preference across commercial plans. Most BCBS and UHC policies now require Tyenne as first-line tocilizumab, with Actemra and other biosimilars requiring step-through documentation.
2. Route dictates benefit channel. IV goes medical benefit with J/Q-codes; SC goes pharmacy benefit. Coordinate PA across both channels when switching routes.
3. Check indication coverage before switching. SSc-ILD requires Actemra SC only. CRS requires Actemra, Tyenne, or Avtozma (not Tofidence). COVID-19 requires Actemra, Tyenne, or Avtozma.
4. Avtozma's SC autoinjector is pending. The BLA supplement for the Avtozma SC autoinjector was received May 2025 with a May 2026 BsUFA date. If approved, this would be the first tocilizumab biosimilar autoinjector, potentially shifting payer preference for SC patients.
5. Transition authorizations proactively. When payers switch preferred products, they often issue proactive authorizations for the preferred biosimilar to avoid care gaps. Confirm the transition date and ensure the new authorization is active before the old one expires.

Sources

• FDA. Biosimilar Product Information. https://www.fda.gov/drugs/biosimilars/biosimilar-product-information
• FDA. Office of Therapeutic Biologics and Biosimilars: Avtozma review. https://www.fda.gov/media/191185/download
• Celltrion. FDA Approves AVTOZMA (tocilizumab-anoh). January 2025. https://www.prnewswire.com/news-releases/us-fda-approves-celltrions-avtozma-tocilizumab-anoh-a-biosimilar-to-actemra-302364951.html
• Aetna. Tocilizumab Clinical Policy Bulletin 0799. https://www.aetna.com/cpb/medical/data/700_799/0799.html
• UnitedHealthcare. Tocilizumab (Actemra, Tofidence, Tyenne) Injection for IV Infusion. Commercial Medical Benefit Drug Policy. https://www.uhcprovider.com/content/dam/provider/docs/public/policies/comm-medical-drug/tocilizumab.pdf
• UnitedHealthcare Community Plan. Tocilizumab Drug Policy (effective April 2026). https://www.uhcprovider.com/content/dam/provider/docs/public/policies/medicaid-comm-plan/tocilizumab-cs.pdf
• Molina Healthcare. Actemra and Biosimilars Coverage Guideline C10265-A. https://www.molinamarketplace.com/
• BCBS Michigan. Tyenne Preferred Tocilizumab Biosimilar Alert. https://providerinfo.bcbsm.com/documents/alerts/2025/202502/alert-20250227-tyenne-pref-tocilizumab-biosimilar-comm-june-1.pdf
• Independence Blue Cross. Biosimilar Adoption for Actemra to Tyenne. https://provcomm.ibx.com/pnc-ibc/news/Pages/Updated_Affordable-treatments-start-with-biosimilars.aspx
• Mass General Brigham Health Plan. Tocilizumab Products PA Policy (effective May 2026). https://resources.massgeneralbrighamhealthplan.org/pharmacy/
• Genentech. Actemra IV Billing Codes. https://www.genentech-pro.com/content/dam/gene/accesssolutions/pdfs/coding/ACTEMRA-Billing-Coding-for-IV.pdf
• Health Net. Tocilizumab and Biosimilars Clinical Policy CP.PHAR.263. https://www.healthnet.com/content/dam/centene/policies/pharmacy-policies/phar/CP.PHAR.263.pdf
• Moda Health / Prime Therapeutics. Tocilizumab Medical Necessity Criteria. https://www.modahealth.com/